Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.40 |
| ▸ | FABP4 | P15090 | 3/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.38 |
| ▸ | FEN1 | P39748 | 1/20 | 0.38 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3178739 | 0.86 | SLC1A3 (0.48) | CA1CA2NR3C1PGR | |
| SCHEMBL3177359 | 0.85 | CA2 (0.56) | CA1CA2ALDH1A1CYP3A4CYP2C19 | |
| SCHEMBL3198456 | 0.85 | CA2 (0.56) | CA1CA2ALDH1A1CYP3A4CYP2C19 | |
| SCHEMBL13335267 | 0.85 | CA2 (0.56) | CA1CA2ALDH1A1CYP3A4CYP2C19 | |
| SCHEMBL3198394 | 0.82 | CA1 (0.49) | CA1CA2NR3C1CNR1ALDH1A1 | |
| SCHEMBL5500999 | 0.79 | CA1 (0.55) | CA1CA2ALOX5APFEN1ALDH1A1 | |
| SCHEMBL3188045 | 0.79 | CA1 (0.46) | CA1CA2ALOX5APFEN1ALDH1A1 | |
| SCHEMBL3322445 | 0.79 | CA1 (0.46) | CA1CA2ALOX5APFEN1ALDH1A1 | |
| SCHEMBL3185176 | 0.78 | ALOX5AP (0.41) | CA1CA2NR3C1ALOX5APFEN1 | |
| SCHEMBL3185242 | 0.77 | CA1 (0.56) | CA1CA2ALDH1A1CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1549306-A4 | SUBSTITUTED PHENYLSULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION | WYETH CORP (US) | 2007-06-06 | — | — | EP | claimed |
| US-20070037778-A1 | Therapy and prophylaxis of Alzheimer's Disease and Down's syndrome; inhibiting beta amyloid production; 2,4-difluoro-N-[(1S,2S)-1-(hydroxymethyl)-2-methylbutyl]benzenesulfonamide | WYETH (US) | 2007-02-15 | — | — | US | claimed |
| US-7166622-B2 | Substituted phenylsulfonamide inhibitors of beta amyloid production | WYETH (US) | 2007-01-23 | — | — | US | claimed |
| EP-1549306-A1 | SUBSTITUTED PHENYLSULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION | Wyeth (US) | 2005-07-06 | — | — | EP | claimed |
| US-20040006050-A1 | Substituted phenylsulfonamide inhibitors of beta amyloid production | WYETH (US) | 2004-01-08 | — | — | US | claimed |
| WO-2003103660-A1 | SUBSTITUTED PHENYLSULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION | WYETH (US) | 2003-12-18 | — | — | WO | claimed |
| US-20100120725-A1 | Substituted Phenylsulfonamide Inhibitors of Beta Amyloid Production | WYETH LLC (US) | 2010-05-13 | — | — | US | disclosed |
| US-7671075-B2 | Substituted phenylsulfonamide inhibitors of beta amyloid production | WYETH (US) | 2010-03-02 | — | — | US | disclosed |
| US-20070037778-A1 | Therapy and prophylaxis of Alzheimer's Disease and Down's syndrome; inhibiting beta amyloid production; 2,4-difluoro-N-[(1S,2S)-1-(hydroxymethyl)-2-methylbutyl]benzenesulfonamide | WYETH (US) | 2007-02-15 | — | — | US | disclosed |
| US-7166622-B2 | Substituted phenylsulfonamide inhibitors of beta amyloid production | WYETH (US) | 2007-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120725-A1 | Substituted Phenylsulfonamide Inhibitors of Beta Amyloid Production | APP, BACE1, PSEN1 | CA1 1302/4885CA2 3420/4885NR3C1 3238/4885 |
| US-20070037778-A1 | Therapy and prophylaxis of Alzheimer's Disease and Down's syndrome; inhibiting beta amyloid production; 2,4-difluoro-N-[(1S,2S)-1-(hydroxymethyl)-2-methylbutyl]benzenesulfonamide | BACE1, APP, PSEN1 | CA1 1214/4885CA2 3464/4885NR3C1 1064/4885 |
| US-20040006050-A1 | Substituted phenylsulfonamide inhibitors of beta amyloid production | APP, BACE1, PSEN1 | CA1 735/4885CA2 2822/4885NR3C1 2513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.